- The development of Immuno-Therapy in Medical Oncology has been practice changing for several frequent tumour types and established Immunotherapy as an additional class of therapeutics.
- Patient selection based of immune biomarkers may be associated with efficacy (predictive factor) but still remains controversial and other biomarkers could help in patient selection.
- The mechanism of action of Immune Check Point Inhibitors differs greatly from conventional cancer treatment and efficacy evaluation needs to be adapted.
- The systemic manipulation of the Immune system has proven efficacy against cancer cells but may also been associated with alteration of normal tissues or organs, targeted by Immune Check Point Inhibitors and consequently auto-immune or auto-immune-like side effects have been reported.
Download the programme
How to apply
Application is via online form. During the application process, you will be required to upload your CV including a list of your publications.
Application for the course is now closed.
Who can apply
While this course is primarily aimed at experienced oncologists resident in Europe, application is open to all ESMO members.
To apply, ESMO membership is mandatory. If you are not an ESMO member, or need to renew your membership, please visit the ESMO membership pages.
Successful applicants benefitted from complimentary course registration and accommodation.
In addition to the course registration and the hotel accommodation, a travel grant of maximum 600 euros was offered to selected applicants as a contribution versus their travel costs. The reimbursement was processed after the course against original invoices/vouchers. Please be aware that visa costs were NOT covered by the travel grant and were the participant's responsibility.
John B.A.G. Haanen, Netherlands
Martin Reck, Germany
Radisson Blu Hotel
1012 CK Amsterdam – Netherlands
T: +31 20 623 1231